FDA committee backs Lilly's prasugrel

FDA staff say Eli Lilly's long-delayed blood thinner prasugrel has clear benefits compared with other anti-clotting meds on the market, but its use may need to be restricted to curb the potential of bleeding side effects; an advisory panel will review the potential new drug later this week. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.